Spoken Alpha
IMDX
Insight Molecular Diagnostics Inc.
Overview
Insight Molecular Diagnostics Inc is a Healthcare company operating in Diagnostics & Research with a $170.8M market cap.
IMDX beat consensus EPS by 0.5% in Q1 FY2026, reported May 13, 2026.
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-139 Q&A exchanges
- Q4 FY2025Earnings2026-03-26
- Q3 FY2025Earnings2025-11-1018 Q&A exchanges
- Q2 FY2025Earnings2025-08-1118 Q&A exchanges
- Q1 FY2025Earnings2025-05-1216 Q&A exchanges
- Q4 FY2024Earnings2025-03-2414 Q&A exchanges
- Q3 FY2024Earnings2024-11-129 Q&A exchanges
- Q2 FY2024Earnings2024-08-107 Q&A exchanges
- Q1 FY2024Earnings2024-05-156 Q&A exchanges
- Q4 FY2023Earnings2024-04-1213 Q&A exchanges
- Q3 FY2023Earnings2023-11-095 Q&A exchanges
- Q2 FY2023Earnings2023-08-106 Q&A exchanges
- Q1 FY2023Earnings2023-05-1120 Q&A exchanges
- Q4 FY2022Earnings2023-04-0319 Q&A exchanges
- Q3 FY2022Earnings2022-11-1023 Q&A exchanges
- Q2 FY2022Earnings2022-08-1114 Q&A exchanges
- Q1 FY2022Earnings2022-05-1126 Q&A exchanges
- Q4 FY2021Earnings2022-03-1028 Q&A exchanges
- Q3 FY2021Earnings2021-11-0915 Q&A exchanges
- Q2 FY2021Earnings2021-08-1011 Q&A exchanges
- Q1 FY2021Earnings2021-05-1720 Q&A exchanges
History
Earnings history
- Q1 FY20262026-05-13EPS$-0.12 vs $-0.26+54.3%Rev$32.0K vs ——EODHD
- Q4 FY20252026-03-26EPS$-0.72 vs $-0.24-100.0%Rev$1.1M vs ——EODHD
- Q3 FY20252025-11-09EPS$-0.34 vs $-0.58+41.4%Rev$260.0K vs ——EODHD
- Q2 FY20252025-08-10EPS$-0.30 vs $-0.63+52.4%Rev$518.0K vs ——EODHD
- Q1 FY20252025-05-11EPS$-0.26 vs $-0.66+60.6%Rev$2.1M vs ——EODHD
- Q4 FY20242025-03-23EPS$-1.93 vs $-1.12-72.3%Rev$1.5M vs ——EODHD
- Q3 FY20242024-11-12EPS$-0.98 vs $-0.44-100.0%Rev$115.0K vs ——EODHD
- Q2 FY20242024-08-08EPS$-0.43 vs $-0.37-16.8%Rev$104.0K vs ——EODHD
- Q1 FY20242024-05-15EPS$-1.13 vs ——Rev$176.0K vs ——EODHD
- Q3 FY20232023-11-08EPS$-0.81 vs $-1.01+19.8%Rev$429.0K vs ——EODHD
- Q2 FY20232023-08-09EPS$-1.03 vs $-0.87-18.4%Rev$463.0K vs ——EODHD
- Q1 FY20232023-05-10EPS$0.04 vs $-0.08+100.0%Rev$297.0K vs ——EODHD
- Q4 FY20222023-03-30EPS$-0.40 vs $-0.09-100.0%Rev— vs ——EODHD
- Q3 FY20222022-11-09EPS$-0.08 vs $-0.11+27.3%Rev$67.0K vs ——EODHD
- Q2 FY20222022-08-09EPS$-0.07 vs $-0.12+41.7%Rev$237.0K vs ——EODHD
- Q1 FY20222022-05-10EPS$-0.11 vs $-0.12+9.4%Rev$380.0K vs ——EODHD
- Q4 FY20212022-03-09EPS$-0.39 vs $-0.12-100.0%Rev— vs ——EODHD
- Q3 FY20212021-11-08EPS$-0.15 vs $-0.12-30.4%Rev$984.0K vs ——EODHD
- Q2 FY20212021-08-09EPS$-0.12 vs $-0.10-19.3%Rev$2.0M vs ——EODHD
- Q1 FY20212021-05-16EPS$-0.05 vs $-0.10+49.3%Rev$1.1M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-13 | $-0.12 | $-0.26 | +54.3% | $32.0K | — | — | EODHD |
| Q4 FY2025 | 2026-03-26 | $-0.72 | $-0.24 | -100.0% | $1.1M | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-0.34 | $-0.58 | +41.4% | $260.0K | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-0.30 | $-0.63 | +52.4% | $518.0K | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.26 | $-0.66 | +60.6% | $2.1M | — | — | EODHD |
| Q4 FY2024 | 2025-03-23 | $-1.93 | $-1.12 | -72.3% | $1.5M | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-0.98 | $-0.44 | -100.0% | $115.0K | — | — | EODHD |
| Q2 FY2024 | 2024-08-08 | $-0.43 | $-0.37 | -16.8% | $104.0K | — | — | EODHD |
| Q1 FY2024 | 2024-05-15 | $-1.13 | — | — | $176.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.81 | $-1.01 | +19.8% | $429.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-1.03 | $-0.87 | -18.4% | $463.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $0.04 | $-0.08 | +100.0% | $297.0K | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-0.40 | $-0.09 | -100.0% | — | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.08 | $-0.11 | +27.3% | $67.0K | — | — | EODHD |
| Q2 FY2022 | 2022-08-09 | $-0.07 | $-0.12 | +41.7% | $237.0K | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $-0.11 | $-0.12 | +9.4% | $380.0K | — | — | EODHD |
| Q4 FY2021 | 2022-03-09 | $-0.39 | $-0.12 | -100.0% | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $-0.15 | $-0.12 | -30.4% | $984.0K | — | — | EODHD |
| Q2 FY2021 | 2021-08-09 | $-0.12 | $-0.10 | -19.3% | $2.0M | — | — | EODHD |
| Q1 FY2021 | 2021-05-16 | $-0.05 | $-0.10 | +49.3% | $1.1M | — | — | EODHD |
Source: EODHD. IMDX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks IMDX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.32 | $2.60 | -10.7% | +7.0% | +9.1% |
| Q4 FY2026 | $2.41 | $2.69 | -10.5% | +7.5% | +6.9% |
| Q3 FY2026 | $2.36 | $2.71 | -13.0% | +5.3% | +8.2% |
| Q2 FY2026 | $2.33 | $2.69 | -13.5% | +6.9% | +9.8% |
| Q1 FY2025 | $2.25 | $2.66 | -15.5% | -2.7% | -5.2% |
| Q4 FY2025 | $2.68 | $2.70 | -0.8% | +2.7% | +2.5% |
| Q3 FY2025 | $2.47 | $2.54 | -2.9% | -0.1% | +1.9% |
| Q2 FY2025 | $2.51 | $2.74 | -8.5% | -0.8% | +0.8% |
| Q1 FY2024 | $2.34 | $2.60 | -9.9% | +6.8% | +8.6% |
| Q4 FY2024 | $2.51 | $2.66 | -5.7% | -2.5% | -0.2% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Maintained2025-13-15
- Q3 FY2025Suspended2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Josh RiggsCEO2 yr 2 mo10 callsCurrentSample
CEO since 2024 • 4/8 beats (50%) • last call held guidance Q1 FY2026
- Andrea S JamesCFO2 yr8 callsCurrentSample
CFO since 2024 • 5/8 beats (63%) • last call held guidance Q1 FY2026
- James Yang LiuVP ACCT, Cntlr, Treasurer, PAO1 yr 3 mono recorded callsCurrentSample
OTHER since 2025 • 3/4 beats (75%) • guidance suspended Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IMDX.
$ curl https://api.spokenalpha.com/v1/companies/IMDXFAQ
Frequently asked about IMDX
Where can I find Insight Molecular Diagnostics Inc.'s (IMDX) earnings call transcripts?
Spoken Alpha indexes IMDX's earnings call transcripts at https://spokenalpha.com/companies/IMDX. Each call links to attributed speakers and parsed analyst Q&A. Insight Molecular Diagnostics Inc.'s own investor relations page is at https://investors.imdxinc.com/.
When was Insight Molecular Diagnostics Inc.'s most recent earnings call?
Insight Molecular Diagnostics Inc. (IMDX) held its most recent earnings call on 2026-05-13, covering fiscal Q1 2026.
What sector is IMDX in?
Insight Molecular Diagnostics Inc. (IMDX) operates in the Healthcare sector (Diagnostics & Research industry).